In contrast to another potential biomarker, atrial natriuretic peptide (ANP), ADM demonstrated a distinct profile of myocardial effects, suggesting its potential as a valuable therapeutic intervention in the post-myocardial infarction setting. This evidence concerns the gene NPPA and myocardial infarction.